Skip to main content

Table 1 Patient baseline characteristics

From: Effect of adjusting the combination of budesonide/formoterol on the alleviation of asthma symptoms

  Total Fixed-dose group Adjusted-dose group
Patients (n) 28 12 16
Mean age (years) 59.7 ± 14.6 65.5 ± 9.8 55.3 ± 16.3
Male/female* 12/16 8/4 4/12
Duration (years) 9.6 ± 7.3 12.5 ± 8.1 7.5 ± 6.0
Atopy/non-atopy 10/18 4/8 6/10
Smoking:
 Smoker 2 1 1
 Ex-smoker 4 2 2
 Never-smoker 22 9 13
Serum IgE (IU/mL) 420 ± 404 382 ± 287 459 ± 514
Serum eosinophils (/μL) 457 ± 331 537 ± 354 394 ± 308
Pulmonary function:
 FVC (% of pred.) 103.2 ± 12.8 96.6 ± 12.1 107.6 ± 11.6
 FEV1 (% of pred.) 84.4 ± 21.5 76.1 ± 28.3 90.0 ± 13.8
 FEV1% 65.5 ± 12.9 60.3 ± 15.7 68.9 ± 9.7
 V50 (% of pred.) 47.3 ± 26.2 40.5 ± 28.7 51.8 ± 24.4
 V25 (% of pred.) 30.6 ± 17.2 28.9 ± 16.4 31.8 ± 18.1
Concomitant drugs:
 BFC alone 12 4 8
 with LTRAa 13 6 7
 with theophylline 9 5 4
This study:
 Observation period (days) 253 ± 59 229 ± 74 271 ± 37
 Frequency of PEF (%) 94.9 ± 9.6 92.4 ± 14.2 96.7 ± 3.2
 Basal dose of BFC (inhalations/day) 3.2 ± 1.0 3.7 ± 0.8 2.9 ± 1.0
 Additional dose of BFC** (inhalations/day) 1.0 ± 1.1 0.0 ± 0.0 2.0 ± 0.5
  1. Mean ± SD
  2. *p < 0.05, **p < 0.01 for comparison between the fixed-dose and adjusted-dose groups
  3. aLeukotriene receptor antagonist